CM Reid

A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

AJ Owen, Jean Spinks, Adrian D. Meehan et al. · Journal of Medical Economics · 2008 · 31 citations · Full text

INERTIA OR INACTION? BLOOD PRESSURE MANAGEMENT AND CARDIOVASCULAR RISK IN DIABETES^‡

AJ Owen, Claudia Retegan, M. D. Rockell et al. · Clinical and Experimental Pharmacology and Physiology · 2008 · 15 citations

Hypertension, Blood Pressure, Kinesiology +20

Six-Month Outcomes After High-Risk Coronary Artery Bypass Graft Surgery and Preoperative Intra-aortic Balloon Counterpulsation Use: An Inception Cohort Study

Edward Litton, Frances Bass, Anthony Delaney et al. · Journal of Cardiothoracic and Vascular Anesthesia · 2018 · 13 citations

FEASIBILITY OF CONDUCTING CARDIOVASCULAR OUTCOME RESEARCH IN AUSTRALIAN GENERAL PRACTICE: RESULTS FROM THE ANBP2 PILOT STUDY

CM Reid, Meredith Nelson, P Beckinsale et al. · Clinical and Experimental Pharmacology and Physiology · 1997 · 10 citations